You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(02359.HK)擬斥300萬英鎊認購一家英國投資基金3%份額
格隆匯 01-10 16:59

格隆匯1月10日丨藥明康德(02359.HK)公佈,2020年1月10日,公司全資子企業Wu Xi Pharma Tech Healthcare Fund I L.P.與Epidarex Capital Management L LP(管理人)簽署Subscription Agreement,約定由Wu Xi Fund I認繳Epidarex Capital IIIUK,LP(投資基金)的300萬英鎊的份額,其中包括43.27英鎊的股權級份額和300萬英鎊的債權級份額,約佔已募集投資基金份額的3.0%。截至本公告日,Wu Xi Fund I尚未支付投資款,後續Wu Xi Fund I將以自有資金根據合夥協議的要求履行投資款的支付義務。

投資基金預計募集總額不超過1.2億英鎊,Wu Xi Fund I本次認繳300萬英鎊後,投資基金已募集9910萬英鎊。投資基金為一家依據英國法律成立的有限合夥企業,主要專注於投資英國診療和醫療器械等領域的早期生命科學企業。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account